Rapid Therapeutic Science Laboratories, Inc. Overview
Pro stress-test →Rapid Therapeutic Science Laboratories is a publicly traded company based in Dallas, Texas, that manufactures and sells inhaler devices containing cannabidiol (CBD), a substance derived from the hemp plant. The company specializes in the development of aerosol delivery systems for CBD products within the health and wellness sector. The company faces significant regulatory and legal challenges that have materially impacted its credibility.
Strategic Profile
Pro stress-test →In September 2023, the SEC filed a civil action alleging that RTSL and its CEO engaged in fraudulent unregistered securities offerings that raised at least $3.25 million from more than 50 investors in 15 states. The SEC's complaint alleged the company made false statements about certification from a non-existent industry board (CMDICB) and falsely claimed major sales contracts and laboratory certifications, with the alleged certification being invented by a Schmidt business associate. The company remains micro-cap with minimal market viability.
Competitive Landscape
Pro stress-test →RTSL operates in a nascent and highly regulated CBD aerosol delivery market with minimal direct competitors due to regulatory restrictions. Potential indirect competition comes from established pharmaceutical inhaler manufacturers (e.g., GlaxoSmithKline, Mylan/Viatris) and consumer CBD product companies, but RTSL's legal challenges and paused operations have effectively eliminated its competitive position. The broader cannabinoid pharmaceutical market remains pre-commercial for most participants.
Industry Context
Rapid Therapeutic Science Laboratories, Inc. operates in Cannabinoid pharmaceutical delivery systems.
Key facts
Founded: 2019 · Headquarters: Dallas, Texas · Employees: 11-50 · Revenue: N/A · Market cap: $114K